RTP Mobile Logo
Year in Review – Multiple Myeloma: 2010-2011
Released November 2011

Year in Review is a unique CME activity that attempts to distill the overwhelming number of data sets and journal articles in multiple myeloma published in 2010 and 2011 into a convenient summary of the most clinically relevant papers and presentations. Featuring commentary from Drs William I Bensinger, Jeffrey L Wolf and Jeffrey A Zonder. (Text and Slide Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 10% of all hematologic cancers and carries with it the worst death to new cases ratio (3:4) among the whole of the subtypes. The American Cancer Society estimated that 20,520 new MM cases will occur in the United States in 2011, with an estimated 10,610 deaths. The treatment of MM has improved dramatically over the past decade, particularly with the advent of novel agents, and the budding landscape surrounding the optimal treatment of MM is both exciting and complex. Knowledge of the many therapeutic advances and changing practice standards is essential to ensuring optimal patient outcomes. To bridge the gap between research and patient care, this CME activity uses the input of cancer experts and community physicians to frame a relevant discussion of recent research advances in myeloma that can be applied to routine clinical practice. This information will help medical oncologists, hematologists and hematology-oncology fellows formulate up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Appraise recent data on therapeutic advances and changing practice standards in MM, and integrate this information into the selection of optimal systemic therapy for patients with MM.
    • Compare and contrast the benefits and risks of lenalidomide- and bortezomib-based induction therapy, and consider the role of combined immunomodulatory/proteasome inhibitor regimens.
    • Utilize biomarkers to risk-stratify patients with MM, and recommend systemic treatment commensurate with prognosis and likelihood of therapeutic response.
    • Recognize the treatment-associated side effects of bortezomib, and offer patients acceptable alternative dosing/administration and/or supportive management interventions to address them.
    • Communicate the benefits and risks of postinduction maintenance therapy to appropriately selected patients with MM.
    • Consider recent Phase III trial data on the use of bisphosphonates for osteolytic and nonosteolytic MM when selecting frequency of administration and total duration of bisphosphonate therapy.
    • Recall the design and eligibility criteria for ongoing clinical trials in newly diagnosed and relapsed MM, and enroll or refer appropriate patients for study participation.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY


    CME credit is no longer available for this issue

    This CME activity contains print and web PowerPoint components. The participant should read the text portion. The text portion of this activity contains edited comments and abbreviated slide set presentations, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    COMMERCIAL SUPPORT

    This activity is supported by educational grants from Celgene Corporation and Millennium: The Takeda Oncology Company.

    PHARMACEUTICAL AGENTS DISCUSSED IN THIS PROGRAM

    This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr BensingerAdvisory Committee: Celgene Corporation, Genzyme Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc; Consulting Agreement: ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company; Paid Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Genzyme Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation. Dr WolfSpeakers Bureau: Celgene Corporation, Centocor Ortho Biotech Services LLC, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation. Dr ZonderConsulting Agreements: Amgen Inc, Medtronic Inc; Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: November 2011
    Expiration date: November 2012

Acknowledge and close

Read print: